S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis
- 937 Downloads
Multiple sclerosis (MS) pathology is characterized by neuroinflammation and demyelination. Recently, the inflammatory molecule S100B was identified in cerebrospinal fluid (CSF) and serum of MS patients. Although seen as an astrogliosis marker, lower/physiological levels of S100B are involved in oligodendrocyte differentiation/maturation. Nevertheless, increased S100B levels released upon injury may induce glial reactivity and oligodendrocyte demise, exacerbating tissue damage during an MS episode or delaying the following remyelination. Here, we aimed to unravel the functional role of S100B in the pathogenesis of MS. Elevated S100B levels were detected in the CSF of relapsing-remitting MS patients at diagnosis. Active demyelinating MS lesions showed increased expression of S100B and its receptor, the receptor for advanced glycation end products (RAGE), in the lesion area, while chronic active lesions displayed increased S100B in demyelinated areas with lower expression of RAGE in the rim. Interestingly, reactive astrocytes were identified as the predominant cellular source of S100B, whereas RAGE was expressed by activated microglia/macrophages. Using an ex vivo demyelinating model, cerebral organotypic slice cultures treated with lysophosphatidylcholine (LPC), we observed a marked elevation of S100B upon demyelination, which co-localized mostly with astrocytes. Inhibition of S100B action using a directed antibody reduced LPC-induced demyelination, prevented astrocyte reactivity and abrogated the expression of inflammatory and inflammasome-related molecules. Overall, high S100B expression in MS patient samples suggests its usefulness as a diagnostic biomarker for MS, while the beneficial outcome of its inhibition in our demyelinating model indicates S100B as an emerging therapeutic target in MS.
KeywordsCerebellar organotypic slice cultures Demyelination Glial inflammatory response Human samples Multiple sclerosis S100B
This work was supported by Medal of Honor L’Oréal for Women in Science (FCT, UNESCO, L’Óreal) and innovation grant (Ordem dos Farmacêuticos) to AF, a post-doctoral grant from Fundação para a Ciência e Tecnologia (FCT-SFRH/BPD/96794/2013) and a DuPré Grant from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) to AB, and by FCT-Pest-OE/SAU/UI4013 to iMed.ULisboa.
The use of human samples was approved by the local institutional review board (IRB), both in Life and Health Sciences Research Institute (ICVS), Portugal, and VU University Medical Center Amsterdam, the Netherlands. Animal use complied with the Portuguese Law and the European Community Directive and followed the Federation of European Laboratory Animal Science Associations (FELASA) guidelines and recommendations concerning laboratorial animal welfare, being performed under the guidance of Adelaide Fernandes, with a FELASA level C certification (scientist), approved by the Portuguese Direção-Geral de Veterinária. This ensured that any suffering or other harmful effects experienced by the animals were minimized and have been weighted against the potential benefits to humans.
- 11.Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H (2000) Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 275(51):40096–40105. doi: 10.1074/jbc.M006993200 CrossRefPubMedGoogle Scholar
- 30.Rejdak K, Petzold A, Kocki T, Kurzepa J, Grieb P, Turski WA, Stelmasiak Z (2007) Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J Neural Transm 114(8):1011–1015. doi: 10.1007/s00702-007-0667-y CrossRefPubMedGoogle Scholar
- 34.Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT, Synowitz H (2000) Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. J Neurotrauma 17(2):113–122CrossRefPubMedGoogle Scholar
- 46.Brozzi F, Arcuri C, Giambanco I, Donato R (2009) S100B protein regulates astrocyte shape and migration via interaction with Src kinase: implications for astrocyte development, activation, and tumor growth. J Biol Chem 284(13):8797–8811. doi: 10.1074/jbc.M805897200 CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Steiner J, Bernstein HG, Bogerts B, Gos T, Richter-Landsberg C, Wunderlich MT, Keilhoff G (2008) S100B is expressed in, and released from, OLN-93 oligodendrocytes: Influence of serum and glucose deprivation. Neuroscience 154(2):496–503. doi: 10.1016/j.neuroscience.2008.03.060 CrossRefPubMedGoogle Scholar
- 51.Deloulme JC, Raponi E, Gentil BJ, Bertacchi N, Marks A, Labourdette G, Baudier J (2004) Nuclear expression of S100B in oligodendrocyte progenitor cells correlates with differentiation toward the oligodendroglial lineage and modulates oligodendrocytes maturation. Mol Cell Neurosci 27(4):453–465. doi: 10.1016/j.mcn.2004.07.008 CrossRefPubMedGoogle Scholar
- 60.Rossi S, Studer V, Motta C, Germani G, Macchiarulo G, Buttari F, Mancino R, Castelli M et al (2014) Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflammation 11:32. doi: 10.1186/1742-2094-11-32 CrossRefPubMedPubMedCentralGoogle Scholar
- 63.Jha S, Srivastava SY, Brickey WJ, Iocca H, Toews A, Morrison JP, Chen VS, Gris D et al (2010) The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci 30(47):15811–15820. doi: 10.1523/JNEUROSCI.4088-10.2010 CrossRefPubMedGoogle Scholar
- 65.Gris D, Ye Z, Iocca HA, Wen H, Craven RR, Gris P, Huang M, Schneider M et al (2010) NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol 185(2):974–981. doi: 10.4049/jimmunol.0904145 CrossRefPubMedPubMedCentralGoogle Scholar
- 67.Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, Schmidt AM, Brown C et al (2003) Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 9(3):287–293. doi: 10.1038/nm831 CrossRefPubMedGoogle Scholar
- 68.Turco F, Sarnelli G, Cirillo C, Palumbo I, De Giorgi F, D’Alessandro A, Cammarota M, Giuliano M et al (2014) Enteroglial-derived S100B protein integrates bacteria-induced Toll-like receptor signalling in human enteric glial cells. Gut 63(1):105–115. doi: 10.1136/gutjnl-2012-302090 CrossRefPubMedGoogle Scholar
- 69.Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S et al (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122(4):1377–1392. doi: 10.1172/JCI58642 CrossRefPubMedPubMedCentralGoogle Scholar
- 70.Pan W, Xin P, Patrick S, Dean S, Keating C, Clawson G (2010) Primer-free aptamer selection using a random DNA library. J Vis Exp (41). doi: 10.3791/2039